Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, Ar1, Ar2, E, a, b, c and z are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both ?2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

Abstract: The disclosure relates to compounds of formula (I): wherein X1, X2, X3, X4, Z1, Z2, Z3, Z4, Ra, Rb, n, Y, and W are as defined in the disclosure, or a salt thereof, or a hydrate or solvate thereof, and to processes for the preparation of these compounds and the therapeutic use thereof.

Abstract: This disclosure relates to compounds of formula (I): wherein G1, G2, G3, G4, n, Y, Z, Z1, Z2, Z3, and Z4 are as defined in the disclosure, or a salt thereof, or a hydrate or solvate thereof, and to processes for the preparation of these compounds and the therapeutic use thereof.

Abstract: Assay methods are disclosed involving specific binding reactions which are simplified compared to known methods. A compound capable of producing chemiluminescence is immobilized on a solid support as is a member of a specific binding pair for capturing an analyte from a sample. An activator compound that activates the chemiluminescent compound and is conjugated to a specific binding pair member is added in excess along with the sample to the solid support. Addition of a trigger solution causes a chemiluminescent reaction at the sites where the activator conjugate has been specifically bound. The assay methods are termed non-separation assays because they do not require removal or separation of excess detection label (activator conjugate) prior to the detection step. The methods are applicable to various types of assays including immunoassays, receptor-ligand assays and nucleic acid hybridization assays.

Abstract: A crystalline solid designated IZM-3 is described which has the X ray diffraction diagram given below. Said solid has a chemical composition expressed as the anhydrous base in terms of moles of oxides by the formula aSiO2:bYO2:cR:dF, in which Y represents at least one tetravalent element other than silicon, R represents at least one organic nitrogen-containing species, and F is fluorine, a, b, c and d respectively representing the number of moles of SiO2, YO2, R and F and a is in the range 0.1 to 1, b is in the range 0 to 0.9, c is in the range 0.01 to 0.5 and d is in the range 0 to 0.5.

Abstract: Syntheses of unsaturated piperidines from piperidones through a silyl piperidine reagent via the Shapiro reaction and palladium-catalyzed cross-coupling reactions with organo halides.

Abstract: Novel compounds are provided, which are useful as linking groups in chemical synthesis, preferably in the solid phase synthesis of oligonucleotides and polypeptides. These compounds are generally photolabile and comprise protecting groups which can be removed by photolysis to unmask a reactive group. The protecting group has the general formula Y, wherein Y is a chemical structure as shown in FIG. 1. Also provided is a method of forming, from component molecules, a plurality of compounds on a support, each compound occupying a separate predefined region of the support, using the protected compounds described above.

Abstract: The present invention provides a silane compound which can be preferably used in an electronics application and the like, as a resin composition which is excellent in heat resistance, pressure resistance, water resistance, low moisture absorption property, low dielectric property, mechanical and chemical stability, and heat conductivity and capable of forming cured articles which hardly reduce physical properties even under severe environments such as high temperature and high pressure and high humidity; its production method, and a resin composition containing the silane compound.

Abstract: Compounds of formula (I): in which X, R1, R2, R3, and R4 are as defined in the disclosure, or an acid addition salt thereof; and therapeutic uses thereof.

Abstract: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4=H; ether or polyether, amino; NO2; NH— carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9, R10); —R5?=H or a C1-C12 alkyl, —R6=H; R; (R or R?)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8=H, C1-C12 alkyl; —R9 and R10=H, R (or R?) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.

Abstract: A coating composition comprising a Photocatalyst Composition comprising a photocatalyst and a pendent silyl ester group, wherein the photocatalyst produces singlet oxygen in the presence of light and ambient air. In certain embodiments, the coating composition further comprises a singlet oxygen scavenger.

Abstract: The present invention is directed to novel process for the preparation of regioselective perylenediimides derivatives, specifically mono and dibrominated derivatives.

Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Abstract: Disclosed herein are mono-functional silylating compounds that may exhibit enhanced silylating capabilities. Also disclosed are method of synthesizing and using these compounds. Finally methods to determine effective silylation are also disclosed.

Abstract: The present invention relates to new types of metal complexes. Such compounds can be used as active components (=functional materials) in a series of different types of applications which can be classed within the electronics industry in the widest sense. The inventive compounds are described by the structure 1 and the formulae (1) to (60).

Abstract: The invention relates to novel chimeric antibiotics of formula I wherein R1 is CH2NHCOR5, heteroarylmethyl, heteroaryloxymethyl or heteroarylaminomethyl; R2 is H, OH, OSO3H, OPO3H2, OCH2OPO3H2, OCOCH2CH2COOH, OCOR6; R3 is H or halogen; R4 is (C1-C3)alkyl, (C1-C3)haloalkyl or cycloalkyl; R5 is alkyl or haloalkyl; and R6 is the residue of a naturally occurring amino acid or of dimethylaminoglycine. These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).

Abstract: The present invention relates to an organic light-emitting diode comprising an anode An and a cathode Ka and a light-emitting layer E which is arranged between the anode An and the cathode Ka and comprises at least one carbene complex and if appropriate at least one further layer, where the light-emitting layer E and/or the at least one further layer comprises at least one compound selected from disilylcarbazoles, disilyldibenzofurans, disilyldibenzothiophenes, disilyldibenzophospholes, disilyldibenzothiophene S-oxides and disilyldibenzothiophene S,S-dioxides, to a light-emitting layer comprising at least one of the aforementioned compounds and at least one carbene complex, to the use of the aforementioned compounds as matrix material, hole/exciton blocker material, electron/exciton blocker material, hole injection material, electron injection material, hole conductor material and/or electron conductor material, and to a device selected from the group consisting of stationary visual display units, mobile visu

Abstract: The present invention involves tetrahydroisoquinoline compounds and their use in the inhibition and/or prevention of tumor growth.

Abstract: The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RAR?, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): wherein X is N or CH; Y is O or S; R1, R2, and R3 are the same or different and are hydrogen or lower alkyl; R4 and R5 are the same or different and are hydrogen, lower alkyl, or halogen; and a bond between a carbon atom to which R1 is attached and a carbon atom to which R2 is attached is a single bond or a double bond; or a salt thereof.

Abstract: Silyl-substituted cyclometalated transition metal complexes have good thermal stability and enabling highly efficient phospholuminescence and an organic electroluminescent device may use the Silyl-substituted cyclometalated transition metal complexes. The transition metal complexes, which are suitably used for forming an organic layer of the organic electroluminescent device, can emit light in the wavelength range of 400-650 nm, and induce white electroluminescence when combined with green or red luminescent materials.

Abstract: A highly crosslinked polysiloxane dye comprising at least 10 Si atoms, including at least one moiety of the formula (I) whose open Si-bonds each are linked to an oxygen atom and open O-bond is linked to a silicon atom in the rest of the polysiloxane, and wherein T is a direct bond or an organic spacer group such as C1-C18alkylene, C2-C12alkenylene, C5-C10cycloalkylene, C5-C10arylene, —C5-C10arylene-(C1-C10alkylene)- each of which may be end-capped towards the linkage to Dye by CO, COO, NR1, CONR1, NR1CONR1, CS, CSS, CSNR1, NR1CSNR1, O, S, SO, SO2, C5-C10cycloalkylene, C5-C10arylene; or T is C3-C18alkylene interrupted, and optionally end-capped towards the linkage to Dye, by CO, COO, NR1, CONR1, NR1CONR1, CS, CSS, CSNR1, NR1CSNR1, O, S, SO, —SO2—, C5-C10cycloalkylene, C5-C10arylene; or is CO; (CH2CH2—O)1-5; COO; N(R1); CON(R1); O; S; SO; SO2; R1 is hydrogen; unsubstituted or substituted, straight-chain or branched, monocyclic or polycyclic, interrupted or uninterrupted C1-C14alkyl; C2-C14alkenyl; C6-C10aryl; C

Abstract: Disclosed is a light emitting device material characterized by containing a specific fluorine compound. This light emitting device material enables to obtain a light emitting device having high luminous efficiency, excellent color purity and excellent durability. Also disclosed is a light emitting device using such a light emitting device material.

Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

Abstract: The present invention relates to a material for an organic electro-optical device and an organic electro-optical device including the same. More particularly, the present invention relates to a material having thermal stability of a glass transition temperature of 120° C. or more and a thermal decomposition temperature of 450° C. or more, and being capable of providing an organic electro-optical device having high efficiency and a long life-span due to less crystallization and improved amorphous properties in a material for an organic electro-optical device. The material for an organic electro-optical device can be used singularly or as a host material in combination with a dopant, and includes an asymmetric fluorene derivative compound. An organic electro-optical device including the material for an organic electro-optical device is also provided.

Abstract: A bipyridine compound represented by the formula (1): wherein R1, R2 and R3 each independently represent a C1-C10 alkyl group which may be substituted etc., and R4, R5, R6, R7 and R8 each independently represent a hydrogen atom etc., a transition metal complex obtained by contacting a bipyridine compound represented by the formula (1) with a compound of a transition metal belonging to Group 9, 10 or 11, and a method for production of a conjugated aromatic compound comprising reacting an aromatic compound (A) wherein one or two leaving groups are bonded to an aromatic ring with an aromatic compound (A) having the same structure as that of the above-mentioned aromatic compound (A) or an aromatic compound (B) being structurally different from the above-mentioned aromatic compound (A) and having one or two leaving groups bonded to an aromatic ring, in the presence of the transition metal complex.

Abstract: Functionalized nanoparticles, which are obtainable by combining in a first step a functionalized dyestuff, a silicon-based spacer and a catalyst, and in a second step reacting the product obtained in the first step with a co-reactive organic silicon, aluminum, zirconium or titanium compound. Optionally, the thus obtained functionalized nanoparticles can be combined or encapsulated with a polymer. The functionalized nanoparticles are useful as colorants and fluorescents in plastics, paints, inks, electronic materials, cosmetic articles, and the like.

Abstract: The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

Abstract: A material for an organic photoelectric device, the material including a compound including a pyridine moiety, the compound being a bipolar organic compound including both a hole transporting unit and an electron transporting unit, the compound being represented by the following Formula 1:

Abstract: The present invention relates to an anthracene compound and an organic electroluminescent display device using the same. Particularly, the present invention relates to an anthracene compound which has good blue light emitting property, transports holes and electrons efficiently to enable an organic electroluminescent display device to have a low voltage, high brightness and long lifetime, and an organic electroluminescent display device using the same.

Abstract: Heterocyclyl-substituted thiazoles of the formula (I), in which the symbols have the meanings given in the description, and also to the agrochemically active salts thereof, and their use for controlling phytopathogenic harmful fungi, and also processes for preparing compounds of the formula (I).

Abstract: The present invention discloses a bis-triphenylsilyl compound and its applications as a host material, electron transport material, or hole transport material in an organic electronic device. The general structure of the bis-triphenylsilyl compound is as follows: where G represents any atomic moiety or single bond of the functional group selected from the group consisting of the following: aryl group, cyclene group, and heterocyclic ring group; and R1˜R32 represent substituents on aryl groups.

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention has a glucokinase activity, and is useful as a medicament such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like.

Abstract: [Problem] Provided is a compound, which exhibits a P2Y12 inhibitory action and is useful as a medical drug, particularly, as a platelet aggregation inhibitor. [Means for Solution] The inventors have eagerly investigated P2Y12 inhibitors. As a result, the inventors have found that a bicyclic heterocyclic compound such as quinazolinedione, isoquinolone, and the like having an amino group substituted with lower alkyl, cycloalkyl, or lower alkylene-cycloalkyl at the specific position exhibits an excellent platelet aggregation inhibitory action, thereby completing the present invention. Since the compound of the invention exhibits excellent P2Y12 inhibitory action and platelet aggregation inhibitory action, it is useful as a platelet aggregation inhibitor.

Abstract: Methods of synthesizing nicotine analogs and derivatives are described. The methods are particularly useful for the regioselective production of enantiomerically pure nicotine analogs having substituents at the C4 position. Intermediates useful for the synthesis of such compounds are also described.

Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Abstract: Compounds of formula I: I wherein at least one of R4 and R5 comprises Si(R6)3 as a substituent selectively attenuate production of A?(1-42) and hence find use in treatment of Alzheimer's disease and related conditions.

Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Abstract: Provided are a bi-functional compound that is positively charged at a first pH and negatively charged at a second pH, a solid support having the bi-functional compound immobilized thereon, and a method of isolating a nucleic acid, including: binding the bi-functional compound with a nucleic acid at a first pH and isolating the nucleic acid from the bi-functional compound at a second pH.

Abstract: Organosilicon compounds are represented by the following formula: wherein R is a hydrolyzable group, R? is an alkyl having 1 to 4 carbon atoms, A is an alkylene having 1 to 6 carbon atoms, X is O or S, Y is —NH— or S, L1 and L2 are C or N, Z and M are —NH—, O or S, R1 to R11 are H, alkyl having 1 to 6 carbon atoms, alkoxy or fluoroalkyl, or amino, m is 1 to 3, and n is 0 to 3. R1 and R2 or R2 and R3 may bonded together. R5 and R6 or R9 and R10 may directly bond together. R4 and R7 or R8 and R11 may form a ring skeleton. Their production processes, pressure-sensitive adhesive compositions, self-adhesive polarizers and LCDs are also disclosed.

Abstract: The present invention is directed to electroluminescent complexes of iridium(III) with silylated, germanylated and stannylated ligands. The invention is further directed to electronic devices in which the active layer includes an electroluminescent Ir(III) complex with silylated, germanylated and stannylated ligands.

Abstract: An organic electroluminescence device includes: a pair of electrodes; and at least one organic layer including a light emitting layer, the light emitting layer being provided between the pair of electrodes, wherein at least one layer of the at least one organic layer contains a compound represented by formula (1): wherein each of Z11 and Z12 independently represents an aromatic heterocyclic ring or an aromatic hydrocarbon ring; R11 represents a hydrogen atom or a substituent, provided that a plurality of R11s are the same or different; m represents an integer of 1 or more; and L1 represents a single bond or an m-valent linking group and is linked to any one of C atoms in R11, Z11 and Z12, provided that when m is 1, L1 does not exist.

Abstract: Aminosilane precursors for depositing silicon-containing films, and methods for depositing silicon-containing films from these aminosilane precursors, are described herein. In one embodiment, there is provided an aminosilane precursor for depositing silicon-containing film comprising the following formula (I): (R1R2N)nSiR34-n ??(I) wherein substituents R1 and R2 are each independently chosen from an alkyl group comprising from 1 to 20 carbon atoms and an aryl group comprising from 6 to 30 carbon atoms, at least one of substituents R1 and R2 comprises at least one electron withdrawing substituent chosen from F, Cl, Br, I, CN, NO2, PO(OR)2, OR, SO, SO2, SO2R and wherein R in the at least one electron withdrawing substituent is chosen from an alkyl group or an aryl group, R3 is chosen from H, an alkyl group, or an aryl group, and n is a number ranging from 1 to 4.

Abstract: A method of inhibiting topoisomerase I mediated DNA cleavage including administering a pharmaceutically effective amount of a compound having the following formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 are independently the same or different and are hydrogen, an alkyl group, an aminoalkyl group, an alkylaminoalkyl group, a haloalkyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, an alkoxyl group, an aryloxy group, a carbamoyloxy group, a halogen, a hydroxyl group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, —C(O)Rf, an amino group, an alkylamino group, a dialkylamino group, —SRc, or R1 and R2 together form a group of the formula —O(CH2)nO— wherein n represents the integer 1 or 2; R3 is H, F, a halogen atom, a nitro group, an amino group, a hydroxyl group, or a cyano group; or R2 and R3 together form —O(CH2)nO— (n=1 or 2); R4 is H, F, a C1-3 alkyl group, a C2-3 alkenyl group, a C2-3 alkynyl group, or a C1-3 alkoxyl group; R5

Abstract: The present invention provides a novel substituted azaindoline intermediate of formula (I) and a method for its synthesis. The novel substitued azaindoline intermediate (I) is provided for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles.

Abstract: A novel pyrazolopyridine derivative is provided which is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine derivative is represented by the following general formula (1): [wherein R1 is a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like, R2 is an optionally substituted alkyl group having 1 to 6 carbon atoms or the like, R5 and R6 are independently a hydrogen atom or a halogen atom, R13 is a hydrogen atom or a halogen atom, n is 0 or 1, is a single or double bond, R3 is a hydrogen atom, a hydroxyl group, or the like, and R4 is a hydrogen atom, a phenyl group, or the like] or a pharmaceutically acceptable salt thereof, and a hydrate thereof.

Abstract: The present invention relates to novel processes for the preparation of a sterically hindered amine ether by reacting a corresponding sterically hindered amine oxide with a ketone or an aldehyde with at least one reactive H in the presence of a peroxydisulphate. Products obtained by this process may be hydrogenated. The compounds made by these processes are particularly effective in the stabilization of polymer compositions against harmful effects of light, oxygen and/or heat and as flame-retardants for polymers.

Abstract: Polyfluorene polymers and copolymers having substantial amounts (10-100%) of fluorenes coupled at the 2 and 5 positions of fluorene are useful as active layers in OLED devices where triplet energies >2.10 eV are required.

Abstract: A 2,2?-bipyridine derivative having a reactive silyl group represented by the following general formula (1): wherein R1 and R2 represent a substituent selected from a monovalent hydrocarbon group, an organoxy group, an acyloxy group, hydroxy group, a halogen atom, hydrogen atom, mercapto group, an amino group, cyano group, cyanate group, isocyanate group, thiocyanate group, and isothiocyanate group; R3 represents a monovalent aliphatic unsaturated hydrocarbon group, an organoxy group, an alkoxy group, an acyloxy group, hydroxy group, a halogen atom, hydrogen atom, mercapto group, an amino group, cyano group, cyanate group, isocyanate group, thiocyanate group, and isothiocyanate group; R4 represents a reactive silyl group represented by the formula: R1R2R3Si, a monovalent hydrocarbon group, or hydrogen atom; R5, R6, R7, and R8 are a monovalent hydrocarbon group or hydrogen atom.

Abstract: A method of preparing an ionic conducting gel in solid form, known as ionogel. The method includes a step of mixing an ionic liquid with at least one molecular precursor containing at least one hydrolyzable group, if necessary in the presence of an acid, such as a carboxylic acid. The mixture is subsequently left to stand for one or more days until a gel is formed by polycondensation of the molecular precursor(s). The gel contains the aforementioned ionic liquid and can be set, in particular in transparent monolithic solid form.